The International Covid-19 Vaccine Program supported by the World Health Organization has established a market to solve the bottleneck of the supply chain that hinders global vaccination efforts.

After Covax plans to struggle to obtain sufficient doses, the new platform aims to match vaccine manufacturers with suppliers of key inputs to help increase production.

As one of the partners behind this initiative, the Epidemic Prevention Innovation Alliance hopes to make it easier for suppliers to redistribute unused materials, including vaccine inputs that have failed to obtain regulatory approval. The platform is also expected to improve the chances of obtaining surplus inventory for manufacturers who do not normally produce vaccines.

CEPI, as the coordinator, stated that it will give priority to the requirements of vaccine manufacturers that have received Covax and WHO emergency use list orders.

CEPI CEO Richard Hatchett, who served as a White House adviser under former U.S. Presidents George W Bush and Barack Obama, said Shortage of critical materials Full capacity operation of vaccine production lines around the world has been stopped.

“Optimizing the use of scarce resources that may be idle-by matching buyers and sellers around the world-may help improve the global vaccine supply through Covax,” he said.

Covax’s goal is to provide 2 billion doses of vaccine by the end of the year, mainly for low- and middle-income countries.So far, it has only provided 118 million vaccines to 135 countries. Previously, Western countries gave priority to vaccinating their populations, and India imposed Export control Manufacturers strive to achieve production goals.

The Covax market will initially focus on six key areas of shortage, including bioreactor bags, lipids required for messenger RNA vaccines, and vials used to transport doses. CEPI said that eventually, the market could also promote the supply of other life-saving drugs and vaccines that are affected by global shortages.

Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers, said that by the end of this year, every adult in the world needs to receive 11 billion doses of the vaccine, and 3 billion doses have been produced so far.

“Delayed delivery of plastic bags for a bioreactor may cause the entire production line to be shut down and delay a batch of thousands of liters of plastic bags for weeks or even months,” he said.

But he added that the world also needs to urgently increase dose sharing and eliminate trade barriers.